Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Aug 13, 2026

Intelligent Bio Solutions Inc. (INBS)

A forensic read on Intelligent Bio Solutions Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.

D · Weak — demands caution

Forensic grade

Distress

Financial health

-33.8

Distress distance

Clean

Earnings quality

Forensic signals

-352.7%

ROE

-1.9%

Revenue growth

The financial-health reading above compares this company's equity at BOOK value, not at what the market currently pays for it — this free snapshot doesn't pull live market data. Treat it as a rough read, not the final word.

This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.

Intelligent Bio Solutions Inc. earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads -33.8, placing it in the Distress zone (based on book value, not market value, since this free snapshot doesn't pull live market data — treat this zone as a rough read, not the final word). 3 forensic signals were flagged in its latest SEC filings, led by receivables vs revenue.

What the filings flag

61d DSO

FY2024→FY2025

Receivables vs revenue. Days sales outstanding moved from 42 to 61 days FY2024→FY2025 (receivables +38% vs revenue -2%). Receivables are outrunning sales — a flag for aggressive revenue recognition or slipping collections. Measured against the same quarter twelve months earlier — like-for-like on the calendar, so an ordinary seasonal build cannot produce it — receivables took longer to collect in 6 consecutive quarters (Dec 2024 +7, Mar 2025 +8, Jun 2025 +29, Sep 2025 +6, Dec 2025 +14, Mar 2026 +24 days). In the latest of them the receivable balance grew +72% against sales +18%, so more of a quarter's billings were still outstanding at the period end than a year earlier — money the company has recognized and not yet been paid.

n/m (stock split)

FY2022–FY2025

Share count (stock split). Diluted share count changed +619% over the last 3 years to FY2025, but that includes a large one-time change around FY2023 consistent with a stock split or reverse split, not gradual buybacks or issuance — a split changes the count with NO effect on any holder's proportional ownership, so the raw +93.0%/yr figure isn't a real buyback/dilution read here.

$4M

FY2023–FY2023

Goodwill impairments. Took $4M of goodwill writedowns across 1 year (FY2023 ($4M)). Writedowns mean past acquisitions underperformed what was paid for them.

Key fundamentals

Latest Revenue$3.1M

Revenue Growth YoY-1.9%

Revenue CAGR (3yr)+91.1%

Net Margin-346.2%

Free Cash Flow-$9.9M

Return on Equity-352.7%

Debt / Equity0.55x

The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Intelligent Bio Solutions Inc.'s actual 10-K/10-Q/8-K filings?

Generate the AI investment read →

No credit card · informational only, not investment advice · see the track record

← Browse all forensic stock analyses

Data from SEC EDGAR public filings · metrics as of Aug 13, 2026. Forensic signals flag probability, not certainty.